Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Immunization with homologous malondialdehyde (MDA)-modified LDL (MDA-LDL) leads to atheroprotection in experimental models supporting the concept that a vaccine to oxidation-specific epitopes (OSEs) of oxidized LDL could limit atherogenesis. However, modification of human LDL with OSE to use as an immunogen would be impractical for generalized use. Furthermore, when MDA is used to modify LDL, a wide variety of related MDA adducts are formed, both simple and more complex. To define the relevant epitopes that would reproduce the atheroprotective effects of immunization with MDA-LDL, we sought to determine the responsible immunodominant and atheroprotective adducts. We now demonstrate that fluorescent adducts of MDA involving the condensation of two or more MDA molecules with lysine to form malondialdehyde-acetaldehyde (MAA)-type adducts generate immunodominant epitopes that lead to atheroprotective responses. We further demonstrate that a T helper (Th) 2-biased hapten-specific humoral and cellular response is sufficient, and thus, MAA-modified homologous albumin is an equally effective immunogen. We further show that such Th2-biased humoral responses per se are not atheroprotective if they do not target relevant antigens. These data demonstrate the feasibility of development of a small-molecule immunogen that could stimulate MAA-specific immune responses, which could be used to develop a vaccine approach to retard or prevent atherogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress
Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P. N., Issa, P. C., Cano, M., Brandstätter, H., Tsimikas, S., Skerka, C., et al. (2011) · Nature · doi:10.1038/nature10449 · Cited by 533
Cited by
van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., Van den Bossche, J., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 674
Self-citationOxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
Que, X., Hung, M.-Y., Yeang, C., Gonen, A., Prohaska, T. A., Sun, X., Diehl, C., Määttä, A., Gaddis, D. E., Bowden, K., et al. (2018) · Nature · doi:10.1038/s41586-018-0198-8 · Cited by 529
“Competition immunoassays were performed to demonstrate specificity 31,32 In brief, 96-well round-bottomed MicroFluor plates (DYNEX Technologies, Chantilly, VA) were coated with various antigens at 5 μg/mL (50 μL per well) in PBS overnight at 4°C.”
Self-citationThe role of B cells in atherosclerosis
Sage, A. P., Tsiantoulas, D., Binder, C. J., & Mallat, Z. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0106-9 · Cited by 298
Self-citationLipoxidation in cardiovascular diseases
Gianazza, E., Brioschi, M., Fernandez, A. M., & Banfi, C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101119 · Cited by 152
Metadata
- Authors
- Gonen, A., Hansen, L. F., Turner, W. W., Montano, E. N., Que, X., Rafia, A., Chou, M.-Y., Wiesner, P., Tsiantoulas, D., Corr, M., VanNieuwenhze, M. S., Tsimikas, S., Binder, C. J., Witztum, J. L., & Hartvigsen, K.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 55
- Issue
- 10
- Pages
- 2137-2155
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W1977878140
- Cited by
- 53
- References
- 4
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. https://app.cochat.ai/papers/10.1194/jlr.m053256
- The paper
- Gonen, A., Hansen, L. F., Turner, W. W., Montano, E. N., Que, X., Rafia, A., Chou, M.-Y., Wiesner, P., Tsiantoulas, D., Corr, M., VanNieuwenhze, M. S., Tsimikas, S., Binder, C. J., Witztum, J. L., & Hartvigsen, K. (2014). Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. Journal of Lipid Research. https://doi.org/10.1194/jlr.m053256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.